Evidence map›Paper›PMID 38734075›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2024

Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality.

G Maddalena, F A Zeineddine, S Rivero-Hinojosa, V N Aushev, S Chowdhury, M A Zeineddine, A M Yousef, T A Yap, A C EINaggar, M C Liu and 4 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Therapeutic targeting of the cGAS-STING pathway in human disease.The Journal of clinical investigation · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

G MaddalenaDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Oncology Unit 1, Veneto Institute of Oncology-IRCCS, Padova; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.
F A ZeineddineDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
S Rivero-HinojosaNatera, Inc., Austin.
V N AushevNatera, Inc., Austin.
S ChowdhuryDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
M A ZeineddineDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
A M YousefDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
T A YapDepartment of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston; The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston.
A C EINaggarNatera, Inc., Austin.
M C LiuNatera, Inc., Austin.
M WhiteDepartment of Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
M J OvermanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
S KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
J P ShenDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jshen8@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Center for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3M
High-Throughput Functional Genomics to Guide Precision Oncology in Gastrointestinal TumorsK22CA234406 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHEN, JOHN PAUL YING CHING · 2019 to 2021
$577k
NCATS NIH HHS KL2 TR000370NCI NIH HHS K22 CA234406NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationHumansPoly-ADP-Ribose Binding ProteinsPoly-ADP-Ribose Binding Proteins

Identifiers

PMID38734075
PMCPMC12476830

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.